News | January 31, 2022
Granules Pharmaceuticals concludes USFDA audit with three minor observations
The audit is a PAI for two of its product applications filed from this facility
The audit is a PAI for two of its product applications filed from this facility
The company does not expect the outcome of this inspection to impact its plans
The company said in a regulatory filing that it was confident of addressing the observations satisfactorily
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
Company experts to participate in eight sessions covering AI-powered clinical development, regulatory innovation, oncology research, and patient engagement
This facility plays an important role in Granules’ global manufacturing and supply network
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
